Explore 3 Stock Ideas & Industry Insights Download Free Report

QuidelOrtho Corp

Company price
10.675 USD -0.03 ( 0.23%)
Last update at 2026-11-09T15:09:00Z
VOLUME
294198
Market Cap
728.96M

Momentum Score

…

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.41
Low
10.80
High
52 Week Price Range
9.92
Low
35.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Quidel Corporation makes rapid diagnostic tests and instruments for point-of-care and clinical laboratories, covering antigen, molecular and immunoassay platforms. Long-term growth drivers include greater adoption of decentralized testing, recurring consumable revenue, expansion of respiratory and multiplex assays and international market penetration, which may appeal to investors seeking exposure to diagnostics' recurring-revenue streams.
Principal risks are revenue volatility as COVID-era testing demand normalizes, regulatory and reimbursement shifts, intense competition from larger diagnostics firms and supply-chain or manufacturing disruptions.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.70
Dividend Yield
-
Revenue TTM
2674.20M
Revenue Per Share
39.27
Gross Profit TTM
1199.60M
Debt / Equity
1.48
ROE
-45.91%
Net Debt
2664.10M
ROCE
-19.36%
Diluted EPS TTM
-14.76

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1107.70M -2131.50M -29.10M 735.90M 900.36M
Net income -1131.80M -2052.00M -10.10M 548.70M 704.23M
Selling general administrative 746.30M 760.60M 748.10M 621.00M 84.25M
Selling and marketing expenses - 6.20M 15.10M - 175.32M
Gross profit 1274.20M 1286.50M 1497.10M 1936.00M 1270.89M
Reconciled depreciation 442.00M 453.40M 457.20M 132.50M 54.38M
Ebit -930.10M -1943.20M 149.80M 843.70M 906.07M
Ebitda -488.10M -1489.80M 607.00M 1104.10M 915.62M
Depreciation and amortization 442.00M 453.40M 457.20M 260.40M 9.56M
Non operating income net other - - - - -5.71M
Operating income -919.20M -1960.90M 139.10M 843.70M 906.07M
Other operating expenses 3649.40M 4743.80M 2858.70M 2286.30M 782.93M
Interest expense 177.60M 188.30M 178.90M 75.70M 5.71M
Tax provision 24.10M -79.50M -19.00M 187.20M 196.13M
Interest income 2.20M 2.60M 5.50M 1.30M -
Net interest income -185.60M -188.90M -176.70M -75.70M -5.71M
Non recurring - - - - -9.56M
Income tax expense 24.10M -79.50M -19.00M 187.20M 196.13M
Total revenue 2730.20M 2782.90M 2997.80M 3266.00M 1698.55M
Total operating expenses 2193.40M 3247.40M 1358.00M 956.30M 355.27M
Cost of revenue 1456.00M 1496.40M 1500.70M 1330.00M 427.66M
Total other income expense net -188.50M -170.60M -168.20M -107.80M -5.71M
Net income from continuing ops -1131.80M -2052.00M -10.10M 548.70M 704.23M
Net income applicable to common shares - - - 548.70M 704.23M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5769.30M 6423.60M 8563.10M 8855.80M 2430.37M
Intangible assets 2563.80M 2735.60M 2934.30M 3123.80M 98.66M
Other current assets 250.50M 135.60M 77.00M 252.10M 4.59M
Total liab 3848.80M 3439.10M 3557.20M 3921.20M 501.01M
Total stockholder equity 1920.50M 2984.50M 5005.90M 4934.60M 1929.36M
Deferred long term liab - - - 3.50M 36.49M
Other current liab 429.80M 341.00M 335.70M 439.80M 210.07M
Common stock 0.10M 0.10M 0.10M - 0.04M
Capital stock 0.10M 0.10M 0.10M 0.00M 0.04M
Retained earnings -996.00M 135.80M 2187.80M 2197.90M 1649.20M
Other liab - - - 294.90M 48.58M
Good will 0.00M 649.50M 2492.00M 2476.80M 337.02M
Other assets - - - 395.80M 39.71M
Cash 169.80M 98.30M 118.90M 292.90M 802.75M
Total current liabilities 966.10M 998.80M 833.80M 1007.00M 323.52M
Current deferred revenue 37.80M 33.50M 36.80M 76.40M 1.92M
Net debt 2664.10M 2583.10M 2495.20M 2531.80M -664.16M
Short term debt 207.60M 372.90M 166.50M 207.50M 10.04M
Short long term debt 178.30M 341.80M 139.80M 207.50M -
Short long term debt total 2833.90M 2681.40M 2614.10M 2824.70M 138.59M
Other stockholder equity 2931.80M 2884.80M 2848.00M 2804.30M 279.77M
Property plant equipment - - - 1520.00M 349.20M
Total current assets 1447.30M 1218.90M 1310.50M 1575.10M 1440.31M
Long term investments - 0.00M 7.40M 21.00M 37.85M
Net tangible assets - - - -666.00M 1622.24M
Short term investments 32.40M 48.40M 48.40M 52.10M 25.76M
Net receivables 417.00M 451.30M 488.40M 453.90M 393.85M
Long term debt 2471.90M 2141.30M 2274.80M 2430.80M -
Inventory 577.60M 533.70M 577.80M 524.10M 198.76M
Accounts payable 279.40M 246.00M 294.80M 283.30M 101.49M
Accumulated other comprehensive income -15.40M -36.20M -30.00M -67.60M 0.35M
Common stock total equity - - - - 0.04M
Retained earnings total equity - - - - 1649.20M
Non currrent assets other 244.40M 249.00M 179.00M 122.70M 19.62M
Non current assets total 4322.00M 5204.70M 7252.60M 7280.70M 990.06M
Capital lease obligations 183.70M 198.30M 199.50M 186.40M 138.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M -149.90M -187.60M -1644.20M -63.69M
Change to liabilities - - - 23.50M -23.34M
Total cashflows from investing activities -192.70M -149.90M - -1644.20M -319.53M
Net borrowings 155.10M 53.40M - 346.20M -0.26M
Total cash from financing activities 155.80M 48.80M -265.80M 252.00M -173.18M
Change to operating activities - - - -83.20M 19.65M
Net income -1131.80M -2052.00M -10.10M 548.70M 704.23M
Change in cash 71.30M -21.00M -174.00M -508.90M 312.81M
Begin period cash flow 98.50M 119.50M 292.90M 802.80M 489.94M
End period cash flow 169.80M 98.50M 118.90M 293.90M 802.75M
Total cash from operating activities 105.20M 83.00M 280.20M 885.30M 805.87M
Issuance of capital stock 6.10M 5.00M 11.60M 26.40M 7.55M
Depreciation 442.00M 453.40M 457.20M 283.60M 54.38M
Other cashflows from investing activities -11.00M -10.70M - 18.40M 36.88M
Change to inventory -148.30M -134.10M -211.60M -116.90M -85.04M
Change to account receivables -117.50M 5.40M 160.00M 150.20M 118.85M
Sale purchase of stock 0.00M -9.60M -7.20M -74.30M -103.44M
Other cashflows from financing activities -5.40M -9.60M -43.80M 2688.20M -77.03M
Change to netincome - - - 106.20M 50.08M
Capital expenditures 188.20M 195.10M 209.30M 140.90M 292.72M
Change receivables - - - - 118.85M
Cash flows other operating - - - - -13.70M
Cash and cash equivalents changes - - - - 313.16M
Change in working capital -125.80M -158.70M -194.90M -53.20M -2.78M
Stock based compensation 45.90M 42.10M 51.60M 48.40M 25.40M
Other non cash items 868.60M 1897.50M -72.20M 57.80M -0.04M
Free cash flow -83.00M -112.10M 70.90M 744.40M 513.14M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
QDEL
QuidelOrtho Corp
-0.03
0.23%
10.68 - 7.23 0.27 0.43 1.39 22.78
ABT
Abbott Laboratories
-0.36
0.33%
109.56 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.14
0.14%
101.66 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-0.84
0.26%
325.03 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-2.15
4.12%
49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

QuidelOrtho Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

9975 Summers Ridge Road, San Diego, CA, United States, 92121

858 552 1100

6500

Name Title Year Born
Mr. Douglas C. Bryant Chairman & CEO 1958
Mr. Robert J. Bujarski J.D. Pres & COO 1969
Ms. Michelle A. Hodges Gen. Counsel 1960
Dr. Werner Kroll Ph.D. Sr. VP of R&D 1957
Mr. Joseph M. Busky CPA Chief Financial Officer 1968
Ms. Louise Brandy Chief Information Officer NA
Mr. Patrick E. Klein Chief Admin. Officer NA
Ruben Argueta Director of Investor Relations NA
Mr. Michael S. Iskra Chief Commercial Officer 1970
Phillip S. Askim VP, Associate Gen. Counsel & Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…